持田製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4534/E00947 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2019/04/05 | 日証協 | 179,739株 | +213.52% | 277,714株 | +90.79% | 243,334株 | +91.24% | 223,927株 | +18.77% |
2019/03/29 | 日証協 | 57,330株 | -19.41% | 145,558株 | +29.24% | 127,243株 | +4.03% | 188,544株 | +104.78% |
2019/03/22 | 日証協 | 71,139株 | -20.47% | 112,626株 | -24.28% | 122,318株 | -18% | 92,073株 | +32.01% |
2019/03/15 | 日証協 | 89,451株 | +42.98% | 148,741株 | +112.31% | 149,162株 | -0.17% | 69,745株 | +30.6% |
2019/03/08 | 日証協 | 62,560株 | -7.03% | 70,060株 | -4.17% | 149,414株 | -12.47% | 53,404株 | -26.99% |
2019/03/01 | 日証協 | 67,293株 | +19.4% | 73,107株 | +41.91% | 170,694株 | +23.16% | 73,143株 | +43.58% |
2019/02/22 | 日証協 | 56,360株 | -28.46% | 51,517株 | +74.1% | 138,594株 | -1.72% | 50,941株 | +50.61% |
2019/02/15 | 日証協 | 78,784株 | -7.19% | 29,590株 | -19.37% | 141,018株 | -2.6% | 33,823株 | +21.52% |
2019/02/08 | 日証協 | 84,884株 | -21.32% | 36,700株 | +63.93% | 144,785株 | -5.11% | 27,833株 | -48.62% |
2019/02/01 | 日証協 | 107,882株 | -5.5% | 22,388株 | -74.56% | 152,584株 | +9.44% | 54,175株 | +3.02% |
2019/01/25 | 日証協 | 114,166株 | -7.3% | 88,005株 | -11.47% | 139,419株 | -7.75% | 52,588株 | +271.23% |
2019/01/18 | 日証協 | 123,158株 | +13.83% | 99,405株 | +20.7% | 151,138株 | +2.6% | 14,166株 | -74.86% |
2019/01/11 | 日証協 | 108,193株 | -43.43% | 82,354株 | +380.25% | 147,312株 | -35.47% | 56,340株 | +933.19% |
2019/01/04 | 日証協 | 191,251株 | +4.05% | 17,148株 | -86.99% | 228,273株 | +3.49% | 5,453株 | -92.43% |
2018/12/28 | 日証協 | 183,812株 | +13.59% | 131,812株 | -9.54% | 220,573株 | +14.9% | 72,070株 | +35.09% |
2018/12/21 | 日証協 | 161,819株 | -1.38% | 145,707株 | +49.88% | 191,973株 | -0.89% | 53,349株 | -36.95% |
2018/12/14 | 日証協 | 164,076株 | -6.02% | 97,217株 | -46.5% | 193,689株 | +9.65% | 84,613株 | -43.58% |
2018/12/07 | 日証協 | 174,590株 | +110.52% | 181,730株 | +189.14% | 176,640株 | +132.49% | 149,963株 | +377.39% |
2018/11/30 | 日証協 | 82,933株 | -3.8% | 62,851株 | +74.71% | 75,979株 | -7.5% | 31,413株 | +53.47% |
※株式分割は考慮していませんのでご注意ください。
Page Top